Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
Vrieling C, Assele SY, Moser L, Sauvé N, Litière S, Fourquet A, Poortmans P, Struikmans H, van Tienhoven G, Bartelink H, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Vrieling C, et al. Among authors: collette l. Eur J Cancer. 2021 Sep;155:28-37. doi: 10.1016/j.ejca.2021.06.018. Epub 2021 Jul 29. Eur J Cancer. 2021. PMID: 34333446
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Bartelink H, et al. Among authors: collette s, collette l. Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Lancet Oncol. 2015. PMID: 25500422 Clinical Trial.
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D, Oei B, Rodenhuis CC, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan DA, Dubois JB, Remouchamps V, Mirimanoff RO, Hart G, Collette S, Collette L, Bartelink H; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Vrieling C, et al. Among authors: collette s, collette l. JAMA Oncol. 2017 Jan 1;3(1):42-48. doi: 10.1001/jamaoncol.2016.3031. JAMA Oncol. 2017. PMID: 27607734 Clinical Trial.
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Antonini N, et al. Among authors: collette l. Radiother Oncol. 2007 Mar;82(3):265-71. doi: 10.1016/j.radonc.2006.09.014. Epub 2006 Nov 28. Radiother Oncol. 2007. PMID: 17126434 Clinical Trial.
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC, Pierart M, Collette L. Bartelink H, et al. Among authors: collette l. J Clin Oncol. 2007 Aug 1;25(22):3259-65. doi: 10.1200/JCO.2007.11.4991. Epub 2007 Jun 18. J Clin Oncol. 2007. PMID: 17577015 Clinical Trial.
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.
Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DA, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van der Hulst M, Wárlám-Rodenhuis CC, Bartelink H; EORTC Radiation Oncology Group. Collette S, et al. Among authors: collette l. Eur J Cancer. 2008 Nov;44(17):2587-99. doi: 10.1016/j.ejca.2008.07.032. Epub 2008 Aug 29. Eur J Cancer. 2008. PMID: 18757193 Clinical Trial.
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F, Poortmans PM, Oei SB, Collette L, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Schinagl DA, Wárlám-Rodenhuis CC, Bartelink H. Jones HA, et al. Among authors: collette l. J Clin Oncol. 2009 Oct 20;27(30):4939-47. doi: 10.1200/JCO.2008.21.5764. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720914 Free PMC article. Clinical Trial.
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H. Vrieling C, et al. Among authors: collette l. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85. doi: 10.1016/s0360-3016(99)00211-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524422 Clinical Trial.
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H; EORTC Radiotherapy, Breast Cancer Groups. Vrieling C, et al. Among authors: collette l. Eur J Cancer. 2003 May;39(7):932-44. doi: 10.1016/s0959-8049(03)00123-0. Eur J Cancer. 2003. PMID: 12706362 Clinical Trial.
248 results